Neurotech International Limited (ASX:NTI)
0.0130
0.00 (0.00%)
At close: Mar 27, 2026
Neurotech International Revenue
Neurotech International had revenue of 4.74M AUD in the half year ending December 31, 2025, with 47.68% growth. This brings the company's revenue in the last twelve months to 7.07M, up 8,687.82% year-over-year. In the fiscal year ending June 30, 2025, Neurotech International had annual revenue of 2.44M, down -23.07%.
Revenue (ttm)
7.07M
Revenue Growth
+8,687.82%
P/S Ratio
2.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
16.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2.44M | -732.95K | -23.07% |
| Jun 30, 2024 | 3.18M | 1.98M | 166.00% |
| Jun 30, 2023 | 1.19M | 586.87K | 96.59% |
| Jun 30, 2022 | 607.62K | 401.25K | 194.44% |
| Jun 30, 2021 | 206.37K | 126.03K | 156.86% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 9.75M |
| Immuron | 7.48M |
| Noxopharm | 3.40M |
| Tissue Repair | 3.38M |
| Avecho Biotechnology | 1.24M |
| Argenica Therapeutics | 1.01M |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |